Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
IRVINE, Calif., March 10, 2017 -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its year end 2016 financial results on Thursday, March 16, after the close of the financial markets.
ChromaDex management will host an investor conference call to discuss the year end results and provide a general business update on Friday, March 17, at 1 p.m. ET.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
| U.S. Toll-Free Number: | (866) 327-8118 | |||||||||
| International Dial-In Number: | (678) 509-7526 | |||||||||
| Conference ID: | 86597553 | |||||||||
| Webcast link: | http://edge.media-server.com/m/p/y5kgkhmd/lan/en | |||||||||
The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com.
The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com.
About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Investor Relations Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 [email protected] ChromaDex Public Relations Contact: Breah Ostendorf, Director of Marketing 949-537-4103 [email protected]
